Verrica Pharmaceuticals Inc
VRCA5.738USD
+0.098+1.74%
交易中 （美东）报价延迟15分钟
526.73M总市值
亏损市盈率 TTM
关于 Verrica Pharmaceuticals Inc 公司
Verrica Pharmaceuticals Inc. 是一家皮肤病治疗公司。该公司专注于开发和商业化皮肤病治疗方法。其产品线包括三种候选产品：YCANTH、VP-315 和 VP-103。YCANTH 是一种专有的药物-设备组合，包含 GMP 控制的斑蝥素配方。我们还在开发 YCANTH，用于治疗普通疣和外生殖器疣的潜在后续适应症。此外，该公司还在开发 YCANTH，用于治疗外生殖器疣或外生殖器疣 EGW。其第二种候选产品 VP-315 是一种基于溶瘤肽的注射疗法，可用于治疗皮肤肿瘤疾病，包括基底细胞癌、非转移性黑色素瘤和非转移性默克尔细胞癌。VP-103 是第二种基于斑蝥素的药物设备组合，可用于治疗跖疣。
公司简介
公司代码VRCA
公司名称Verrica Pharmaceuticals Inc
上市日期Jun 15, 2018
CEODr. Jayson Rieger
员工数量71
证券类型Ordinary Share
年结日Jun 15
公司地址44 West Gay Street
城市WEST CHESTER
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编19380
电话14844533300
网址https://verrica.com/
公司代码VRCA
上市日期Jun 15, 2018
CEODr. Jayson Rieger
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Jayson Rieger
Dr. Jayson Rieger
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
88.99K
+50.90%
Mr. David Zawitz
Mr. David Zawitz
Chief Operating Officer
Chief Operating Officer
11.00K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00
--
Dr. Gavin Corcoran
Dr. Gavin Corcoran
Independent Director
Independent Director
2.00
--
Dr. Noah L. Rosenberg, M.D.
Dr. Noah L. Rosenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Lawrence Eichenfield, M.D.
Dr. Lawrence Eichenfield, M.D.
Independent Director
Independent Director
--
--
Mr. John J. Kirby
Mr. John J. Kirby
Interim Chief Financial Officer, Interim Principal Financial Officer
Interim Chief Financial Officer, Interim Principal Financial Officer
--
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Chairman of the Board
Chairman of the Board
--
--
Mr. Mark A. Prygocki, Sr.
Mr. Mark A. Prygocki, Sr.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Jayson Rieger
Dr. Jayson Rieger
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
88.99K
+50.90%
Mr. David Zawitz
Mr. David Zawitz
Chief Operating Officer
Chief Operating Officer
11.00K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00
--
Dr. Gavin Corcoran
Dr. Gavin Corcoran
Independent Director
Independent Director
2.00
--
Dr. Noah L. Rosenberg, M.D.
Dr. Noah L. Rosenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Lawrence Eichenfield, M.D.
Dr. Lawrence Eichenfield, M.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
持股股东
占比
Manning (Paul B.)
53.85%
Caligan Partners, LP
9.72%
Armistice Capital LLC
9.26%
BKB Growth Investments LLC
6.46%
Boothbay Fund Management, LLC
3.04%
Other
17.67%
持股股东
持股股东
占比
Manning (Paul B.)
53.85%
Caligan Partners, LP
9.72%
Armistice Capital LLC
9.26%
BKB Growth Investments LLC
6.46%
Boothbay Fund Management, LLC
3.04%
Other
17.67%
股东类型
持股股东
占比
Individual Investor
57.67%
Hedge Fund
19.53%
Investment Advisor
6.74%
Corporation
6.74%
Investment Advisor/Hedge Fund
5.58%
Research Firm
0.28%
Venture Capital
0.06%
Bank and Trust
0.04%
Pension Fund
0.01%
Other
3.35%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
182
8.94M
96.65%
+3.24M
2025Q1
194
69.94M
75.99%
+19.16M
2024Q4
191
70.39M
77.72%
+35.42M
2024Q3
179
29.67M
67.28%
-5.27M
2024Q2
173
33.68M
79.75%
-1.13M
2024Q1
171
34.51M
82.01%
-2.46M
2023Q4
170
35.04M
83.66%
+1.56M
2023Q3
172
32.74M
78.91%
-2.85M
2023Q2
169
31.35M
77.69%
+2.98M
2023Q1
171
29.74M
73.94%
+2.67M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Manning (Paul B.)
31.38M
33.93%
+17.53M
+126.54%
Nov 26, 2024
Caligan Partners, LP
8.99M
9.72%
+1.56M
+21.04%
Mar 31, 2025
Armistice Capital LLC
8.57M
9.26%
-353.60K
-3.96%
Mar 31, 2025
BKB Growth Investments LLC
5.98M
6.46%
+5.98M
--
Nov 22, 2024
Boothbay Fund Management, LLC
2.81M
3.04%
+220.30K
+8.52%
Mar 31, 2025
The Vanguard Group, Inc.
2.36M
2.55%
+481.41K
+25.61%
Mar 31, 2025
Stalfort (John A)
1.87M
2.03%
+238.09K
+14.56%
Apr 01, 2025
BlackRock Institutional Trust Company, N.A.
1.12M
1.22%
+32.58K
+2.98%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.02M
1.1%
+541.22K
+113.40%
Mar 31, 2025
Rieger (Jayson)
889.88K
0.96%
+300.19K
+50.91%
Apr 01, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Invesco NASDAQ Future Gen 200 ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Simplify Propel Opportunities ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
查看更多
Invesco NASDAQ Future Gen 200 ETF
占比0%
iShares Russell 2000 Growth ETF
占比0%
Global X Russell 2000 ETF
占比0%
Proshares Ultra Russell 2000
占比0%
Avantis US Small Cap Equity ETF
占比0%
iShares Micro-Cap ETF
占比0%
Simplify Propel Opportunities ETF
占比0%
iShares Russell 2000 ETF
占比0%
ProShares Hedge Replication ETF
占比0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
